Skip to content
  • Clinical Studies
  • Pharma GMP
  • Pharma Tips
  • Stability Studies
  • Pharma Books
  • Schedule M

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • SOP – Blog Post
  • Toggle search form

SOP for Freeze-Thaw Stability Testing of Emulsion Formulations

Posted on By

SOP for Freeze-Thaw Stability Testing of Emulsion Formulations

Freeze-Thaw Stability Testing of Emulsion Formulations

1) Purpose

The purpose of this SOP is to describe the procedure for conducting freeze-thaw stability testing on emulsion formulations. This testing helps to evaluate the stability of emulsions when subjected to repeated freeze-thaw cycles, simulating potential environmental conditions during transportation or storage.

2) Scope

This SOP applies to all personnel involved in the freeze-thaw stability testing of emulsion formulations. It outlines the preparation, storage, and evaluation of emulsions after exposure to freezing and thawing cycles.

3) Responsibilities

  • Formulation Scientists: Responsible for preparing emulsion samples for freeze-thaw testing and ensuring uniformity across batches.
  • QC Team: Responsible for conducting the freeze-thaw tests and documenting the results at predefined intervals.
  • QA Team: Responsible for reviewing the results to ensure compliance with GMP standards.

4) Procedure

4.1 Sample Preparation

  • 4.1.1 Prepare the emulsion formulations according to the manufacturing protocol, ensuring sample uniformity.
  • 4.1.2 Label the samples with the batch number, preparation date, and storage conditions.
  • 4.1.3 Store samples at -20°C for 24 hours to simulate freezing conditions before testing begins.
See also  SOP for Conducting Long-Term Stability Studies on Emulsions

4.2 Freeze-Thaw Cycle Testing

The following steps outline the freeze-thaw testing process for emulsion formulations:

  • 4.2.1 Freezing Phase: Store the emulsion samples at -20°C for 24 hours. Ensure that all samples are completely frozen before proceeding to the thawing phase.
  • 4.2.2 Thawing Phase: Remove the samples from the freezer and allow them to thaw at room temperature (25°C) for 4 hours. Ensure that all samples are completely thawed.
  • 4.2.3 Repeat Cycles: Repeat the freezing and thawing process for 3-5 cycles, depending on the protocol.

4.3 Physical Stability Tests

After completing the freeze-thaw cycles, perform the following tests to evaluate the stability of the emulsion formulation:

  • 4.3.1 Droplet Size Distribution: Measure the droplet size distribution using dynamic light scattering (DLS) or laser diffraction to detect any changes in droplet size after freeze-thaw cycles.
  • 4.3.2 Zeta Potential: Measure the zeta potential of the emulsion to evaluate changes in surface charge, which can indicate potential instability.
  • 4.3.3 Viscosity: Measure the viscosity of the emulsion to assess any changes in flow behavior due to phase separation or instability.
  • 4.3.4 Visual Inspection: Perform a visual inspection of the emulsion to detect any signs of phase separation, coalescence, or sedimentation.
See also  SOP for Preparation of Multilamellar Vesicles (MLVs)

4.4 Data Recording and Analysis

  • 4.4.1 Record all test results in the Freeze-Thaw Stability Test Report (see Annexure 1 for the template).
  • 4.4.2 Compare test results before and after freeze-thaw cycles to identify any changes in stability.
  • 4.4.3 Analyze the data to determine if the emulsion formulation maintains stability after freeze-thaw stress.

4.5 Acceptance Criteria for Stability

The emulsion formulation is considered stable under freeze-thaw conditions if the following criteria are met:

  • 4.5.1 Droplet size remains within acceptable limits with no significant coalescence or size increase.
  • 4.5.2 Zeta potential values remain stable, indicating good colloidal stability.
  • 4.5.3 No significant changes in viscosity are observed, indicating no phase separation or instability.
  • 4.5.4 No visible signs of phase separation, coalescence, or sedimentation are detected.
See also  SOP for Optimization of Droplet Size in Emulsion Formulations

5) Abbreviations

  • DLS: Dynamic Light Scattering
  • QC: Quality Control
  • QA: Quality Assurance

6) Documents

  • Freeze-Thaw Stability Test Report
  • Batch Manufacturing Record (BMR)
  • Droplet Size Distribution Report
  • Zeta Potential Measurement Report
  • Viscosity Measurement Report

7) References

  • ICH Q1A: Stability Testing of New Drug Substances and Products
  • FDA Guidelines for Emulsion-Based Drug Products

8) SOP Version

Version 1.0

Annexure

Annexure 1: Freeze-Thaw Stability Test Report Template

Time Point Storage Condition Droplet Size (nm) Zeta Potential (mV) Viscosity (cP) Visual Inspection Operator Initials
Initial -20°C 100-300 nm -30 to -50 mV 10 cP No separation Operator Name
After 1 Cycle Room Temperature 100-300 nm -30 to -50 mV 10 cP No separation Operator Name
Liposome and Emulsion Formulations Tags:Antioxidants in emulsions, API incorporation in emulsions, API incorporation in liposomes, Chemical stability testing liposomes, Cosmetic emulsion formulation, Emulsion droplet size analysis, Emulsion formulation SOP, Emulsion microbiological stability, Emulsion stability testing, Freeze-thaw stability testing, Heat-sensitive liposomes, High-shear mixing emulsions, Liposomal drug delivery SOP, Liposomal vaccines SOP, Liposome formulation SOP, Liposome particle size analysis, Liposome preparation procedure, Liposome size distribution, Liposome stability testing, Nanoemulsion SOP, Parenteral emulsion preparation, pH-responsive emulsions, Physical stability liposomes, Self-emulsifying drug delivery systems (SEDDS), Thin-film hydration liposomes

Post navigation

Previous Post: SOP for Incorporation of Peptides in Nanoparticle-Based Formulations
Next Post: SOP for Preparation of Nanoparticles for Gene Delivery

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version